Monoclonal Antibody to CD43 (T-Cell Marker)(Clone : SPN/839)

It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.

Flow Cytometry (1-2ug/million cells); Immunofluorescence (1-2ug/ml); ,Western Blot (1-2ug/ml); ,Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes);

For Research Use Only. Not for use in diagnostic/therapeutics procedures.

Subcellular location:	Nucleus, Nucleus
Post transnational modification:	CD43 cytoplasmic tail: Sumoylated.
Tissue Specificity:	Cell surface of thymocytes, T-lymphocytes, neutrophils, plasma cells and myelomas.
BioGrid:	112571. 13 interactions.

There are currently no product reviews Write a review on this product!